Acadia reports Phase 2 RADIANT topline results for remlifanserin in Alzheimer’s disease psychosis

Acadia reported Phase 3-enabling topline results from the Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis. The trial showed a modest efficacy signal at the higher dose, with the lower dose offering little benefit. Safety looked broadly comparable to placebo, with no new concerns flagged for heart rhythm, motor function, or cognition. Two ongoing Phase 3 studies will continue, with the program amended to drop the lower-dose arm. Detailed Phase 2 results will be presented at the CTAD conference on Nov. 16-19, 2026 in Boston. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ACADIA Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref. ID: 20260924048898) on September 24, 2026, and is solely responsible for the information contained therein. (C)